Deutsche Bank upgrades GSK to ‘buy’

by | Mar 17, 2023

Analysts at Deutsche Bank upgraded biopharmaceutical firm GSK from ‘hold’ to ‘buy’ on Friday as they updated estimates and made changes to their net present value assumptions.
Deutsche Bank stated HIV makes up more than 20% of GSK sales, likely in excess of one-third of underlying earnings, and was “instrumental” to the long-term outlook.

The German bank, which also hiked its target price on the stock from 1,500.0p to 1,700.0p, said the net result of its fresh look at the stock saw it increase sales/EBITA estimates by low-to-mid-single digits over the mid-term and mid-to-high-single digits over the long term.

“At a 4% dividend/9% FCF yield, 9x FY23E P/E for +3/+8% sales/EPS CAGRs FY22-26E, we think GSK is too cheap if there is any semblance of sustainability through FY27/28, something we now think is probable courtesy of long acting injectables in HIV and RSV, with potential upside from bepirovirsen in HepB,” said DB.

Reporting by Iain Gilbert at

Related articles

RBC Capital cuts Rentokil price target

RBC Capital cuts Rentokil price target

(Sharecast News) - RBC Capital Markets cut its price target on Rentokil Initial on Wednesday to 575p from 610p as it downgraded forecasts for forex and a greater back-end loading of TMX synergies, but said it believes the long-term story remains intact. The bank said...

Citi stays cautious about Experian on falling US credit flows

Citi stays cautious about Experian on falling US credit flows

(Sharecast News) - Citi has lifted its target price for data analytics and consumer credit reporting group Experian after a near-30% jump in the stock in the past two months, but has maintained a 'neutral' rating on the stock. Citi said back in August that while US...

Trending stories

Join our mailing list

Subscribe to our mailing list to receive regular updates!